A Phase IV Observational Study Evaluating the Efficacy and Safety of Anlotinib in Combination With Penpulimab as First-line Treatment in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 27 May 2022
At a glance
- Drugs Catequentinib (Primary) ; Penpulimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 16 May 2022 Status changed from not yet recruiting to recruiting.
- 14 Apr 2022 New trial record